Timothy Ray Brown: The Berlin Patient, HIV Cure, and Key Facts

What happened to Timothy Ray Brown

Timothy Ray Brown, known as the Berlin Patient, was an American living with HIV who received a stem cell transplant in 2007 to treat leukemia. The donor carried a CCR5 delta-32 mutation that conferred natural resistance to HIV. After intensive chemotherapy, Brown stopped antiretroviral therapy and, after years of careful monitoring, showed no signs of detectable virus. For more than a decade he remained in sustained remission without medication, making him the first and one of the most closely documented cases of what is considered a potential HIV cure. This profile explains the medical facts, verified outcomes, and lasting scientific impact of his case.

Timeline of key events

Brown’s medical timeline is documented through clinical records and follow-up studies. Below is a concise verification table summarizing major dates, events, and their significance for HIV cure research.

Date or Period	Event	Why it matters
1995	Diagnosed with HIV	Established baseline infection status before transplant.
2006	Diagnosed with acute myeloid leukemia	Required allogeneic stem cell transplant, enabling introduction of CCR5 delta-32 resistance.
February 2007	First stem cell transplant from CCR5 delta-32 homozygous donor	Provided the genetic modification central to treatment and potential HIV control.
July 2007	Second stem cell transplant (buconditioning)	Improved engraftment and durability of the donor immune system.
2008–2009	HIV undetectable after discontinuation of antiretroviral therapy	Demonstrated sustained virological remission without medication.
2010–2020	Multiple independent assays found no replication-competent HIV reservoir	Supported claims of a sterilizing remission, not just clinical control.
2022	Reported diagnosis of leukemia recurrence	Triggered further treatment; eventual outcome highlighted limits of transplant-based approaches.
2024	Reported death from cancer complications	Marked the end of a landmark case while sustaining research into cure mechanisms.

Medical context and mechanisms

Brown’s cure is best understood as an indirect strategy: a transplant for cancer incidentally provided HIV resistance through donor genetics. The key elements include CCR5 antagonism, conditioning regimens that ablate the host immune system, and successful engraftment of donor hematopoietic cells. Important distinctions exist between an sterilizing cure (no replication-competent virus detected) and a functional cure (controlled without therapy). His case does not establish a standard treatment pathway due to toxicity but informs cure-focused research designs.

The CCR5 delta-32 mutation

CCR5 is a co-receptor HIV uses to enter CD4 T cells. A homozygous deletion (delta-32) prevents functional receptor expression on the cell surface, blocking CCR5-tropic HIV entry. While rare in most populations, individuals homozygous for this mutation have strong natural resistance to infection and, in the context of a transplant, can enable donor-derived cells to largely replace recipient CD4s that lack CCR5. This genetic barrier underpins the biological rationale for choosing a CCR5-delta-32 homozygous donor for Brown’s transplant.

Conditioning and engraftment

Conditioning chemotherapy and immunosuppression served two purposes: to make space for donor stem cells (immunosuppression) and to reduce the host immunologic environment that could control viral reservoirs. Successful multi-lineage engraftment meant Brown’s immune system was largely derived from donor hematopoietic stem cells, which populate immune tissues and may be inherently less targetable by CCR5-using HIV. The interplay of cell killing, replacement, and selection shaped the observed remission.

Clinical outcomes and assessment

Brown’s clinical outcome was evaluated through consensus methodologies favored by cure-oriented research networks. These included prolonged ART-free follow-up, sensitive assays for intact proviral DNA, and lymph tissue sampling when clinically feasible. Reported results consistently indicated an undetectable viral load and no replication-competent virus in standard and investigatory probes. This outcome is described as a sustained remission rather than eradication per se, reflecting careful scientific language around HIV persistence.

Impact on research and legacy

The Berlin Patient case provided a proof-of-concept that CCR5-targeted allogeneic hematopoietic stem cell transplantation can yield sustained HIV remission. It directly motivated subsequent efforts such as the London Patient, the New York Patient, and related trials exploring similar strategies with reduced-intensity conditioning. Brown’s experience underscored the difference between cure and long-term control and highlighted feasibility, risks, and ethical considerations. His legacy endures in cure trial design, inclusion of functional assays, and emphasis on rigorous definitions for remission.

Key facts at a glance

The following table distills verified, high-information attributes of Timothy Ray Brown’s medical history and its relevance to HIV cure science.

Attribute	Verified Detail	Source Type
Common name	Berlin Patient	Medical literature & reports
HIV status at diagnosis	HIV-positive (clade B)	Clinical records
Cancer diagnosis	Acute myeloid leukemia (relapsed)	Clinical reports
Donor CCR5 genotype	Homozygous CCR5 delta-32 mutation	Genotyping studies
Transplant date	February 2007 (first), July 2007 (second)	Clinical timeline
ART discontinuation	2008	Physician-reported & published follow-up
Duration of sustained remission	Approximately 12 years without detectable virus	Longitudinal studies
Final cancer outcome	Leukemia recurrence (2022) and later death from cancer complications (2024)	Published case updates

Clarifying common points of confusion

Not a standard HIV treatment: The approach is too risky for routine care and is not recommended outside clinical trials.
Not guaranteed sterilization: Some intact proviral DNA was detectable in tissue samples, but no replication-competent virus was found in prospective assays.
CCR5-tropic virus focus: Most documented cures involve CCR5-tropic viruses; CXCR4-using strains remain a consideration in similar cases.
Individual variability: Outcomes depend on conditioning intensity, donor genetics, and the host environment; each case must be evaluated independently.

FAQs

Below are concise answers to frequently asked questions based on verified clinical and research sources.

What caused Timothy Ray Brown’s HIV remission? A stem cell transplant from a donor with homozygous CCR5 delta-32 mutation replaced his immune system with cells naturally resistant to CCR5-tropic HIV, leading to sustained remission after antiretroviral therapy discontinuation.
Was Timothy Ray Brown the first person cured of HIV? He is widely cited as the first person with sustained remission of HIV without antiretroviral therapy following a transplant, often referred to as a functional or sterilizing cure in scientific literature.
Did Timothy Ray Brown die from HIV? No. He died from cancer complications in 2024. His HIV remained in sustained remission at the time of his death.
Is a CCR5 delta-32 homozygous donor required for similar outcomes? Yes, for the same approach; other attempts have used donors with this mutation because it blocks CCR5 co-receptor expression and hinders CCR5-tropic HIV entry.
What is the difference between remission and cure in HIV research? Remission refers to sustained control of virus without therapy; cure implies long-term control after treatment cessation. Sterilizing remission means no replication-competent virus detected, while virologic remission indicates undetectable plasma viremia under current assay limits.